Pipeline

Product
Indication
Single agent/ Combination
Preclinical
Phase I
Phase II
Phase III / Pivotal
Filed
Approved

Cosibelimab

Anti-PD-L1 Antibody

cSCC

Metastatic

Single Agent

cSCC

Locally
Advanced

Single Agent

Olafertinib

3rd Generation EGFR Inhibitor

NSCLC

EGFR mut+

Cosibelimab +
Olafertinib

Earlier Stage Programs

Earlier Stage Programs

CK-103

CK-302

CK-303

BET Inhibitor

Solid Tumor

Anti-GITR

Solid Tumor

Anti-CAIX

Solid Tumor

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.